本帖最后由 maicon08 于 2023-4-28 15:12 编辑
4 c+ ?; E3 q$ L$ Z: f5 w+ Y) Y) \, c W( o, L$ ]8 c5 l5 t
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月2日-6月6日召开。ASCO年会是世界上规模最大、学术水平最高、最具权威的临床肿瘤学会议，致力于癌症的预防、治疗和改善患者管理，以展示肿瘤的基础研究和临床最新研究为特点，讨论当前国际先进的治疗方法。随着中国临床研究在肿瘤领域的快速成长，中国在世界肿瘤领域中也发挥着日益重要的作用。此次会议上，中国大陆研究Oral Abstract Session入选16项，另外Clinical Science Symposium和Rapid Abstract Session部分各有1项中国研究入选，共18项。1 Q4 e, d4 h7 `4 V- W) Z. a
% F0 K7 X8 V4 b% x' _1 H- _$ f/ Hhttps://www.163.com/dy/article/I3BTTPRD053438SI.html
% ?2 ]& }, O# n8 K& R: _; u2 U) R6 J; K$ O7 D& A
/ f# c% q" H3 u" r( [5 h5 u
在研疗法-免疫治疗
# X7 H* ~: k9 x1 Q" KDevelopmental Therapeutics—Immunotherapy) w7 g0 Q9 k4 ]; |# P
' i4 @" N. Y) A1 i' ]8 N摘要号：2507 标题：Phase I study of the bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 combined with SHR2554, an EZH2 inhibitor, in patients with previously treated advanced lymphoma and solid tumors. 报告人：丰恺超 单位：JFJ总医院第一医学中心 3 k3 y- H% ]/ P# n; h; g% p+ d
在研疗法-分子靶向药物和肿瘤生物学4 W ^! B( X+ a
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
- D& x% N* c- b/ c* [& F1 j# t: {摘要号：3001 标题：BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study. 报告人：张力 单位：中山大学肿瘤防治中心
" J5 m) D7 R" s4 l
摘要号：3007 标题：A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors. 报告人：周清 单位：广东省人民医院 ; V; S8 v9 p* D2 o# m; `) N% z
胃肠道肿瘤-结直肠癌和肛门癌9 _9 l! _4 r: c9 J# _
Gastrointestinal Cancer—Colorectal and Anal 摘要号：3505 标题：Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial. 报告人：张剑威 单位：中山大学附属第六医院 ( [' A; q" p* \1 x
胃肠道肿瘤-胃食管癌、胰腺癌和肝胆癌 Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary 7 `# x7 T: p1 {6 ?. x
摘要号：4001 标题：Perioperative PD-1 antibody toripalimab plus SOX or XELOX chemotherapy versus SOX or XELOX alone for locally advanced gastric or gastro-oesophageal junction cancer: Results from a prospective, randomized, open-label, phase II trial. 报告人：袁庶强 单位：中山大学肿瘤防治中心
3 [; c/ H; y) G
妇科肿瘤 Gynecologic Cancer 5 V3 G* R7 H" Q
摘要号：5516 标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial. 报告人：田文娟 单位：复旦大学附属肿瘤医院
6 y4 z) {% o. u0 l5 P- q: Z% ^
头颈肿瘤
3 a p; J5 p" C) S; ~ Head and Neck Cancer
, ]- V$ a, S# }$ I, a* T4 b. p摘要号：6000 标题：Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-5-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: A multicentre, open-label, randomised, controlled, phase 3 trial. 报告人：唐林泉 单位：中山大学肿瘤防治中心 6 a6 {0 l; m" O* Q z# H
摘要号：6001 标题：Induction chemotherapy plus radiotherapy alone versus cisplatin-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: An open-label, non-inferiority, randomized phase 3 trial. 报告人：陈明远 单位：中山大学肿瘤防治中心
, {" w! Y7 p h
摘要号：LBA6002 标题：PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM). 报告人：马骏 单位：中山大学肿瘤防治中心 : m: I4 Q9 Z2 N
血液系统恶性肿瘤-淋巴瘤和慢性淋巴细胞白血病 Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
! M0 z: V/ p/ L) E4 [摘要号：7503 标题：Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8). 报告人：蔡清清 单位：中山大学肿瘤防治中心
( b' x- c; _9 U% W( l% ]/ E6 S! P
血液系统恶性肿瘤-浆细胞疾病5 g9 I0 B7 F6 T" N
Hematologic Malignancies—Plasma Cell Dyscrasia ( t e; q4 g% b: B7 t
摘要号：8005 标题：Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM). 报告人：杜鹃 单位：上海长征医院
+ B; \ R2 q* j7 N$ ]
肺癌-非小细胞局部-区域性/小细胞/其他胸部肿瘤4 g V* k' z V) [, l2 {# J
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
+ S6 ]% r( a- N$ D2 z6 X7 E摘要号：8501 标题：Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): Interim event-free survival (EFS) analysis of the phase III NEOTORCH study. 报告人：陆舜 单位：上海交通大学医学院附属胸科医院 5 M' k' S0 @& n4 A" u2 M
肺癌-转移性非小细胞肺癌
" l: |0 N8 {0 h/ R6 @0 h% E Lung Cancer—Non-Small Cell Metastatic
" c; h- g) r! |1 W9 X摘要号：9001 标题：Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant (EGFRm+) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis. 报告人：吴一龙 单位：广东省人民医院 i9 d; O; V: \# b& g8 H
% `, B$ _7 I9 A7 U摘要号：9002 标题：Sunvozertinib for the treatment of NSCLC with EGFR Exon20 insertion mutations: The first pivotal study results. 报告人：王孟昭 单位：北京协和医院
3 O1 i+ g5 y* n( c9 }; b
摘要号：9003 标题：Final overall survival and biomarker analyses of CHOICE-01: A double-blind randomized phase 3 study of toripalimab versus placebo in combination chemotherapy for advanced NSCLC without EGFR/ALK mutations. 报告人：邬麟 单位：湖南省肿瘤医院
* ]1 c) q5 T9 f4 d6 p o8 O1 O, \
黑色素瘤/皮肤癌6 g" N7 a( [8 t w0 \% h/ M
Melanoma/Skin Cancers 摘要号：9508 标题：Temozolomide plus cisplatin versus toripalimab (anti-PD-1) as adjuvant therapy in resected mucosal melanoma. 报告人：郭军 单位：北京大学肿瘤医院 ) a( `- N& E/ Y z& H# a
快速摘要报告- y+ n# i. E% X
Rapid Abstract Session 摘要号：LBA1013 标题：TORCHLIGHT: a randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC). 报告人：江泽飞 单位：JFJ总医院第五医学中心
- O4 \( k% B8 t2 K
临床科学研讨会
0 I- U' }9 | B& q' D" g+ l Clinical Science Symposium 摘要号：11510 标题：The clinical value of tumor-informed minimal residual disease detection in sarcoma. 报告人：尹军强 单位：中山大学附属第一医院 9 U g( h8 Z3 I. c% m
0 M4 {* ~" a6 d$ K3 d; w
| 
发表于 2023-4-28 14:46:30
楼主
发表于 2023-4-28 14:53:34
发表于 2023-4-28 20:42:18
，中肿在保持鼻咽癌和食道癌这些优势的同时，头颈癌和血癌也逐渐发力了
